Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982065 | 0.95 | SIGMAR1 (0.90) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL1901358 | 0.91 | SIGMAR1 (0.84) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL1073695 | 0.90 | SIGMAR1 (0.82) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL6479844 | 0.86 | SIGMAR1 (0.75) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL981182 | 0.85 | SIGMAR1 (0.74) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL11627783 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL1316135 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM5CHRM3ALDH1A1CHRM1 | |
| SCHEMBL13640016 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL28391152 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM5CHRM3CA12CA1 | |
| SCHEMBL1314827 | 0.84 | SIGMAR1 (0.72) | SIGMAR1CHRM5CHRM3ALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| CN-117123156-A | Continuous flow process for key intermediate of prazol | 长沙创新药物工业技术研究院有限公司 | 2023-11-28 | — | — | CN | claimed |
| WO-2023137387-A2 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| WO-2023137373-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2023-07-13 | — | — | US | claimed |
| EP-4178615-A1 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2023-05-17 | — | — | EP | claimed |
| US-11225490-B2 | Prodrugs of secondary amine compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-18 | — | — | US | claimed |
| WO-2022011358-A1 | TETRAHEDRAL ANTIBODIES | BIOMOLECULAR HOLDINGS LLC (US) | 2022-01-13 | — | — | WO | claimed |
| JP-2003515526-A | — | — | 2003-05-07 | — | — | JP | claimed |
| EP-1252133-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-10-30 | — | — | EP | claimed |
| CN-1356981-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-03 | — | — | CN | claimed |
| EP-1192129-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2002-04-03 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4495186-A | SALT FORMATION WITH A DIHYDROXYALUMINUM-A-HYDROXYCARBAXYLIC ACID | CAMILLO CORVI S.P.A. (IT) | 1985-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220115-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | SIGMAR1 3256/4885CHRM5 4572/4885CHRM3 4049/4885 |
| US-20230220116-A1 | TETRAHEDRAL ANTIBODIES | FCGR3B, FCGR2A, FCGR1A | SIGMAR1 3256/4885CHRM5 4572/4885CHRM3 4049/4885 |
| US-11225490-B2 | Prodrugs of secondary amine compounds | HNMT, MAOB, UGT1A1 | SIGMAR1 45/4885CHRM5 538/4885CHRM3 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.